Skip to main content
. 2023 Oct 4;14:1270796. doi: 10.3389/fendo.2023.1270796

Table 4.

Outcome of DTC with respect to BRAFV600E, TERT promoter mutations or both.

Total
No. (%)
NED
No. (%)
PD
No. (%)
P value
BRAFV600E mutation 137 (46.3) 74/175 (42.3) 63/121 (52.1) 0.12
TERT promoter mutations 72 (24.3) 27/175 (15.4) 45/121 (37.2) <0.0001
BRAFV600E+TERT promoter mutations 34 (11.5) 8/175 (4.9) 26/121 (21.5) <0.0001

NED, no evidence of disease; PD, persistent disease.